Interleukin (IL)-20 is a proinflammatory
cytokine of the
IL-10 family and involved in
rheumatoid arthritis,
atherosclerosis,
stroke, and
osteoporosis. However, the pathophysiological roles of
IL-20 in liver injury have not been extensively studied. We explored the involvement of
IL-20 in liver injury and the therapeutic potential of
IL-20 antagonists for treating
liver fibrosis. Compared with normal liver tissue from healthy individuals, the amount of
IL-20 was much higher in hepatocytes and hepatic stellate cells in liver biopsies from patients with
fibrosis,
cirrhosis, and
hepatocellular carcinoma.
Carbon tetrachloride (CCl4) treatment induced
IL-20 that further up-regulated the expression of
transforming growth factor (TGF)-β1 and p21(WAF1) and resulted in cell cycle arrest in the Clone-9 rat hepatocyte cell line.
IL-20 activated quiescent rat hepatic stellate cells (HSCs) and up-regulated TGF-β1 expression.
IL-20 also increased TGF-β1,
tumor necrosis factor (TNF)-α, and
type I collagen (Col-I) expression, and promoted the proliferation and migration of activated HSCs. Serum
IL-20 was significantly elevated in mice with short-term and long-term CCl4 -induced liver injury. In mice with short-term liver injury, anti-IL-20
monoclonal antibody (7E) and anti-IL-20 receptor (IL-20R1)
monoclonal antibody (51D) attenuated hepatocyte damage caused by CCl4, TGF-β1, and
chemokine production. In mice with long-term liver injury, 7E and 51D inhibited CCl4 -induced cell damage, TGF-β1 production,
liver fibrosis, HSC activation, and extracellular matrix accumulation, which was caused by the reduced expression of tissue inhibitors of
metalloproteinases as well as increased
metalloproteinase expression and Col-I production. IL-20R1-deficient mice were protected from short-term and long-term liver injury.
CONCLUSION: